Financial Gravity Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Financial Gravity Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$0	Hold	33	–	–	﹤0.01%	986
2025 Q4	$0	Hold	33	–	–	﹤0.01%	963
2025 Q3	$0	Buy	+33	New	–	﹤0.01%	977
2025 Q1	$0	Buy	+33	New	–	﹤0.01%	1060
2019 Q4	$3K	Sell	132 -15	-10%	-$44	﹤0.01%	1325
2019 Q3	$0	Hold	147	–	–	﹤0.01%	1720
2019 Q2	$0	Hold	147	–	–	﹤0.01%	1860
2019 Q1	$1K	Buy	+147	New	+$496	﹤0.01%	1289
2018 Q3	$1K	Sell	213 -11	-5%	-$27	﹤0.01%	1346
2018 Q2	$1K	Sell	224 -5	-2%	-$14	﹤0.01%	1370
2018 Q1	$1K	Buy	+229	New	+$625	﹤0.01%	1364

Other funds holding PDLI

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Financial Gravity Asset Management's PDLI Position: Q1 2026 in Review

Financial Gravity Asset Management held its PDL BioPharma, Inc. (PDLI) position steady in Q1 2026 at 33 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #986.

Financial Gravity Asset Management first reported a position in PDLI in Q1 2018 and has held it in 11 quarters since. The position peaked at $3K in Q4 2019. 6 funds tracked by Wall St. Rank hold PDLI as of Q1 2026.

Financial Gravity Asset Management held 33 shares of PDL BioPharma, Inc. worth $0 as of Q1 2026.
Financial Gravity Asset Management left its PDL BioPharma, Inc. share count unchanged in Q1 2026.
PDL BioPharma, Inc. made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q1 2026, its #986 holding.
Financial Gravity Asset Management first reported a position in PDL BioPharma, Inc. in Q1 2018 and has held it in 11 quarters since.
Financial Gravity Asset Management's PDL BioPharma, Inc. position peaked at $3K in Q4 2019.
6 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2026.

Based on Financial Gravity Asset Management's 13F filing for Q1 2026, filed 8 May 2026.